FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine)
2349  

FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine)

The U.S. Food and Drug Administration approved Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the ...

April 10, 2019
News